Class Action Lawsuit Announced for Corcept Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CORT?
Source: PRnewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for stock purchasers between October 31, 2024, and December 30, 2025, indicating potential compensation risks for investors.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026, highlighting the urgency of legal proceedings and the necessity for investor participation.
- Compensation Mechanism Explained: Investors joining the class action may receive compensation without any upfront costs, making this no-risk compensation arrangement appealing to a broader range of investors.
- Lawsuit Background Revealed: The lawsuit alleges that Corcept misrepresented clinical trial data supporting the NDA for relacorilant, leading to investor losses upon the revelation of the true circumstances, showcasing significant deficiencies in the company's information disclosure practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 34.820
Low
50.00
Averages
91.00
High
121.00
Current: 34.820
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics to Announce Q4 Earnings on February 24
- Earnings Announcement: Corcept Therapeutics is set to release its Q4 earnings on February 24, with consensus EPS estimates at $0.33 and revenue expected to reach $254.94 million, reflecting a 40.2% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen no upward revisions and one downward adjustment, while revenue estimates also faced one downward revision, indicating a cautious market outlook on the company's performance.
- Market Response: Despite challenges, Corcept's Korlym product maintains its market position amid a patent dispute with Teva, demonstrating resilience in a competitive landscape.
- Future Outlook: Although Relacorilant's performance fell short of expectations, analysts believe that the potential upside in the ovarian cancer market remains unpriced, potentially providing growth opportunities for the company moving forward.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for stock purchasers between October 31, 2024, and December 30, 2025, indicating potential compensation risks for investors.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026, highlighting the urgency of legal proceedings and the necessity for investor participation.
- Compensation Mechanism Explained: Investors joining the class action may receive compensation without any upfront costs, making this no-risk compensation arrangement appealing to a broader range of investors.
- Lawsuit Background Revealed: The lawsuit alleges that Corcept misrepresented clinical trial data supporting the NDA for relacorilant, leading to investor losses upon the revelation of the true circumstances, showcasing significant deficiencies in the company's information disclosure practices.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Allegations Overview: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, indicating a lack of transparency from the company.
- Stock Price Plunge: Following the FDA's issuance of a Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30, 2025, to $34.80, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Investors can contact KSF law firm to discuss their legal rights and how to participate in the lawsuit, demonstrating the firm's commitment to supporting investors in recovering economic losses due to corporate misconduct.
See More
Corcept Faces Class Action Lawsuit After 50.4% Stock Price Drop
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Corcept on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025, with a deadline of April 21, 2026, for lead plaintiff applications.
- FDA Concerns Raised: The complaint alleges that Corcept's New Drug Application (NDA) faced scrutiny from the FDA due to inadequate clinical evidence, contradicting the company's claims of strong support from clinical trials.
- Stock Price Plummet: Following the announcement of a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock price fell dramatically from $70.20 to $34.80, marking a 50.4% decline and resulting in significant losses for investors.
- Legal Consultation Encouraged: The law firm is urging affected investors to reach out for legal rights discussions and potential claims, highlighting the firm's commitment to protecting investor interests.
See More
Corcept Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Kirby McInerney LLP has initiated a class action lawsuit on behalf of investors who suffered losses from October 31, 2024, to December 30, 2025, with a deadline of April 21, 2026, for lead plaintiff applications, emphasizing the urgency for affected investors to act.
- FDA Concerns: Corcept claimed strong clinical trial support for its NDA submission, yet the FDA raised repeated concerns about the adequacy of clinical evidence, indicating a significant risk of non-approval, which undermined investor confidence in the company's prospects.
- Stock Price Plunge: Following the FDA's Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80, reflecting a drastic shift in market sentiment regarding the company's future.
- Subsequent Impact: On January 30, 2026, the FDA's CRL detailed concerns about Corcept's clinical development, leading to an additional stock decline of $4.74, or approximately 10.6%, indicating ongoing investor skepticism about the company's viability and future approvals.
See More
Corcept Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, reflecting strong investor response to potential misleading statements by the company.
- Lawsuit Allegations: The lawsuit alleges that defendants made false representations regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, the company's lead candidate for treating hypercortisolism, which could significantly impact the company's reputation and stock price.
- Investor Action Guidance: Investors wishing to serve as lead plaintiffs must file papers by April 21, 2026, highlighting the urgency of the lawsuit and the protection of investor rights in this matter.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993, showcasing its extensive experience and success in class action litigation, which may bolster investor confidence in the lawsuit.
See More
Corcept Therapeutics to Announce Q4 Earnings on February 24
- Earnings Announcement: Corcept Therapeutics is set to release its Q4 earnings on February 24, with consensus EPS estimates at $0.33 and revenue expected to reach $254.94 million, reflecting a 40.2% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen no upward revisions and one downward adjustment, while revenue estimates also faced one downward revision, indicating a cautious market outlook on the company's performance.
- Market Response: Despite challenges, Corcept's Korlym product maintains its market position amid a patent dispute with Teva, demonstrating resilience in a competitive landscape.
- Future Outlook: Although Relacorilant's performance fell short of expectations, analysts believe that the potential upside in the ovarian cancer market remains unpriced, potentially providing growth opportunities for the company moving forward.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for stock purchasers between October 31, 2024, and December 30, 2025, indicating potential compensation risks for investors.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026, highlighting the urgency of legal proceedings and the necessity for investor participation.
- Compensation Mechanism Explained: Investors joining the class action may receive compensation without any upfront costs, making this no-risk compensation arrangement appealing to a broader range of investors.
- Lawsuit Background Revealed: The lawsuit alleges that Corcept misrepresented clinical trial data supporting the NDA for relacorilant, leading to investor losses upon the revelation of the true circumstances, showcasing significant deficiencies in the company's information disclosure practices.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Allegations Overview: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, indicating a lack of transparency from the company.
- Stock Price Plunge: Following the FDA's issuance of a Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30, 2025, to $34.80, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Investors can contact KSF law firm to discuss their legal rights and how to participate in the lawsuit, demonstrating the firm's commitment to supporting investors in recovering economic losses due to corporate misconduct.
See More
Corcept Faces Class Action Lawsuit After 50.4% Stock Price Drop
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Corcept on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025, with a deadline of April 21, 2026, for lead plaintiff applications.
- FDA Concerns Raised: The complaint alleges that Corcept's New Drug Application (NDA) faced scrutiny from the FDA due to inadequate clinical evidence, contradicting the company's claims of strong support from clinical trials.
- Stock Price Plummet: Following the announcement of a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock price fell dramatically from $70.20 to $34.80, marking a 50.4% decline and resulting in significant losses for investors.
- Legal Consultation Encouraged: The law firm is urging affected investors to reach out for legal rights discussions and potential claims, highlighting the firm's commitment to protecting investor interests.
See More
Corcept Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Kirby McInerney LLP has initiated a class action lawsuit on behalf of investors who suffered losses from October 31, 2024, to December 30, 2025, with a deadline of April 21, 2026, for lead plaintiff applications, emphasizing the urgency for affected investors to act.
- FDA Concerns: Corcept claimed strong clinical trial support for its NDA submission, yet the FDA raised repeated concerns about the adequacy of clinical evidence, indicating a significant risk of non-approval, which undermined investor confidence in the company's prospects.
- Stock Price Plunge: Following the FDA's Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80, reflecting a drastic shift in market sentiment regarding the company's future.
- Subsequent Impact: On January 30, 2026, the FDA's CRL detailed concerns about Corcept's clinical development, leading to an additional stock decline of $4.74, or approximately 10.6%, indicating ongoing investor skepticism about the company's viability and future approvals.
See More
Corcept Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, reflecting strong investor response to potential misleading statements by the company.
- Lawsuit Allegations: The lawsuit alleges that defendants made false representations regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, the company's lead candidate for treating hypercortisolism, which could significantly impact the company's reputation and stock price.
- Investor Action Guidance: Investors wishing to serve as lead plaintiffs must file papers by April 21, 2026, highlighting the urgency of the lawsuit and the protection of investor rights in this matter.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993, showcasing its extensive experience and success in class action litigation, which may bolster investor confidence in the lawsuit.
See More
